Volume 5, Number 2 (Mar 2017)                   Res Mol Med (RMM) 2017, 5(2): 0-0 | Back to browse issues page


XML Print


Abstract:   (70 Views)
Background: Deoxyribozymes (DZs) can play a role as gene expression inhibitors at the mRNA level. Among DZs, the 10-23 deoxyribozyme has significant potentials for treatment of diseases. Designed DZ includes a catalytic core made of 15 deoxyribonucleotides and two binding arms consist of 6-12 nucleotides for site specific binding to target RNA and hydrolysis. The enzyme has characteristic features for cleavage of the RNA target in between an unpaired purine (A, G) and a paired pyrimidine (C or U). In this study, 10-23 Dz is designed for the coding region of the α-peptide of a lacZ gene.
Material and Methods: The primary sequence of a plasmid with α-complementation ability was taken from addgene database. To confirm sequence validity, ExPassy was used to analyze related ORFs for the retrieved sequence. The ORF with identical sequence as in α-peptide was selected in the reverse complement sequence. Subsequently, the secondary structure of the α-peptide was analyzed in DINAmelt webserver and Mfold software. Then intended target site was selected inside the coding region of the α-peptide. The Dzs sequence was designed for the target site with nucleotide binding arms.
Results and conclusion: The resulted Dz in this study can be used as a promising catalytic DNA inside bacterial cells for blue-white screening. Criteria such as biological stability and catalytic rate of such enzymes must be evaluated in vivo and in vitro.
 
     
Type of Study: Research | Subject: Biostatistics
Received: 2017/08/10 | Accepted: 2017/09/5 | Published: 2017/09/5